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Abstract
Background: Tropical calcific pancreatitis (TCP) is a type of chronic pancreatitis unique to developing countries in tropical
regions and one of its important features is invariable progression to diabetes, a condition called fibro-calculous pancreatic
diabetes (FCPD), but the nature of diabetes in TCP is controversial. We analysed the recently reported type 2 diabetes (T2D)
associated polymorphisms in the TCF7L2 gene using a case-control approach, under the hypothesis that TCF7L2 variants should
show similar association if diabetes in FCPD is similar to T2D. We also investigated the interaction between the TCF7L2 variants
and N34S SPINK1 and L26V CTSB mutations, since they are strong predictors of risk for TCP.
Methods: Two polymorphisms rs7903146 and rs12255372 in the TCF7L2 gene were analyzed by direct sequencing in 478 well-
characterized TCP patients and 661 healthy controls of Dravidian and Indo-European ethnicities. Their association with TCP
with diabetes (FCPD) and without diabetes was tested in both populations independently using chi-square test. Finally, a meta
analysis was performed on all the cases and controls for assessing the overall significance irrespective of ethnicity. We
dichotomized the whole cohort based on the presence or absence of N34S SPINK1 and L26V CTSB mutations and further
subdivided them into TCP and FCPD patients and compared the distribution of TCF7L2 variants between them.
Results: The allelic and genotypic frequencies for both TCF7L2 polymorphisms, did not differ significantly between TCP patients
and controls belonging to either of the ethnic groups or taken together. No statistically significant association of the SNPs was
observed with TCP or FCPD or between carriers and non-carriers of N34S SPINK1 and L26V CTSB mutations. The minor allele
frequency for rs7903146 was different between TCP and FCPD patients carrying the N34S SPINK1 variant but did not reach
statistical significance (OR = 1.59, 95% CI = 0.93–2.70, P = 0.09), while, TCF7L2variant showed a statistically significant
association between TCP and FCPD patients carrying the 26V allele (OR = 1.69, 95% CI = 1.11–2.56, P = 0.013).
Conclusion: Type 2 diabetes associated TCF7L2 variants are not associated with diabetes in TCP. Since, TCF7L2 is a major
susceptibility gene for T2D, it may be hypothesized that the diabetes in TCP patients may not be similar to T2D. Our data also
suggests that co-existence of TCF7L2 variants and the SPINK1 and CTSB mutations, that predict susceptibility to exocrine damage,
may interact to determine the onset of diabetes in TCP patients.
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Background
Pancreatitis is generally believed to be a disease where
pancreas is injured by enzymes that are normally secreted
by the acinar cells. Chronic Pancreatitis (CP) is a continu-
ing or relapsing inflammatory process of pancreas leading
to exocrine and/or endocrine insufficiency. Tropical cal-
cific pancreatitis (TCP) is a type of CP unique to develop-
ing countries in tropical region [1]. An important feature
of TCP is its consistent progression to diabetes, commonly
known as fibro-calculous pancreatic diabetes (FCPD)
[1,2]. FCPD is thought to be a type of diabetes secondary
to TCP, resulting from destruction of beta-cell mass in the
pancreas [3]. However, several studies have shown partial
preservation of beta-cell mass [3] and evidence of insulin
resistance to a similar degree as seen in type 2 diabetes
(T2D) patients [4], suggesting that the diabetes in FCPD
could be type T2D, while others have not found insulin
resistance to be a major factor in FCPD [5]. It was believed
earlier that diabetes specific complications do not occur in
FCPD [6], but prevalence of retinopathy, [7] nephropathy
and neuropathy [8] in FCPD patients has been reported to
be no different from matched group of patients with T2D.
Similarly, although the diabetes is severe and insulin
requiring in both FCPD and type 1 diabetes (T1D), FCPD
patients rarely develop ketoacidosis, in contrast to the
T1D patients, who are ketosis prone [9,10].
Mutations in the serine protease inhibitor, Kazal type 1
(SPINK1) [11-15], cystic fibrosis transmembrane regula-
tor (CFTR) [16], cathepsin B (CTSB) [17] and recently,
chymotrypsin C (CTRC) [18] genes have been identified
to be associated with TCP but they mostly associate with
pancreatic exocrine dysfunction. No study has yet investi-
gated the genetic basis of diabetes in TCP and FCPD.
Based on the suggestive linkage of T2D to chromosome
10q, a microsatellite, DG10S478, within intron 3 of tran-
scription factor 7-like 2 (TCF7L2) gene was found to be
strongly associated with T2D [19]. An association of a var-
iant of the gene, rs7903146 along with other SNPs in link-
age disequilibrium with this polymorphism was first
reported in Islandic, Danish and in the US cohort [19].
Subsequently this association was replicated in other pop-
ulations like Indian [20,21], French [22], U.K [23] and
Finnish populations [24], and these variants account for
the highest T2D risk confirmed to date [25]. TCF7L2 gene
variants have also been proposed to play important role in
T1D because of its effects on blood glucose homeostasis
[26]; however a recent study failed to find any association
and age-of-onset effect of T1D with rs7903146 SNP in
TCF7L2 gene [27]. This suggested that a T2D mechanism
mediated by polymorphisms in TCF7L2 does not partici-
pate in the etiology of T1D, thus susceptibility factors for
T2D could be different from those involved in T1D.
Hence, investigating a known susceptibility factor for T1D
or T2D can help in understanding the type and mecha-
nism of diabetes in FCPD patients.
As the type of diabetes in FCPD is not clearly understood,
we used association of TCF7L2 variants with T2D as a
marker to decipher the type of diabetes in FCPD. Since
there are suggestions that TCP is the pre-diabetic stage of
FCPD, we also analyzed the association of TCF7L2 poly-
morphisms in TCP patients. We hypothesized that we
would observe an association of variants in the TCF7L2
gene with FCPD, if diabetes in these patients is T2D. Since
diabetes in TCP is also thought to be due to destruction of
endocrine pancreatic cells secondary to destruction of
exocrine pancreas, we investigated the interaction
between the TCF7L2 variants and N34S SPINK1 and L26V
CTSB  mutations and explored whether presence of
TCF7L2 variants in patients with these mutations predis-
poses them to FCPD.
Methods
Patients and controls
478 unrelated individuals (320 males and 158 females)
were diagnosed as TCP (n = 286) or FCPD (n = 192)
patients based on the established WHO criteria [28]. Of
these, 333 patients were of Dravidian ethnicity and 145
belonged to Indo-European ethnicity. Six hundred and
sixty one age matched individuals (332 males and 329
females) comprising of 259 Dravidians and 402 Indo-
Europeans without any complaints and evidence of pan-
creatitis were included as controls [17,20]. Both patients
and the controls filled a detailed questionnaire and signed
a written informed consent for genetic analysis. The Insti-
tutional Ethics Committee of all the institutes approved
the study following the Indian Council of Medical
Research guidelines for research on human subjects.
Genetic analysis
Genomic DNA from all the patients and healthy volun-
teers were utilized for this study. Primers, amplifying seg-
ments of TCF7L2 gene harboring SNPs rs7903146 and
rs12255372 were adopted from our earlier study [20].
PCR products were purified and sequenced individually
on both the strands using Big-dye terminator cycle
sequencing ready kit (Applied Biosystems, Foster City,
CA) on an ABI3730 Genetic Analyzer (Applied Biosys-
tems Foster City, CA). In case of unclear sequence data, we
repeated direct sequencing under various conditions until
the genotype was determined correctly. Ten percent of the
genotyping results were validated on tetra primer based
analysis for the 2 SNPs [20] and no discrepancy was
observed.
Statistical analysis
The allele and genotype frequencies were calculated for
the SNPs (table 1) in cohorts of both ethnicities separatelyBMC Medical Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2350/9/80
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as well as together and to analyze deviation from the
Hardy-Weinberg equilibrium, observed and expected gen-
otype frequencies were compared by Markov simulation
based goodness of fit test [29]. Chi-square test was used to
analyze the statistical significance of the difference in
allelic distribution of various polymorphisms in patients
and controls (DeFinitte; http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). For assessing the overall significance irrespec-
tive of ethnicities, the meta-analysis statistic was used and
the forest plots were generated under the fixed effect
model using Comprehensive Meta Analysis http://
www.Meta-Analysis.com software version 2.2.046 and the
Q test was used to test for homogeneity of groupings [30].
The whole cohort was dichotomized initially based on the
presence or absence of N34S SPINK1  and L26V CTSB
mutations and then the two groups were subdivided into
TCP and FCPD patients and distribution of TCF7L2 vari-
ants was compared between them. Unless indicated spe-
cifically, a p-value of 0.05 was considered significant in all
the analyses. This study with random selection of patients
and controls has 80% power to detect an effect with an OR
as low as 1.3 at α = 0.05 and 95% power at the OR of 1.46,
which was identified in our earlier study on T2D subjects
[20].
Results and discussion
The two polymorphisms rs7903146 and rs12255372 in
the TCF7L2 gene, reported to be most strongly associated
with T2D, were analyzed in a cohort of TCP and FCPD
patients and controls belonging to Dravidian and Indo-
European ethnicities. It is believed by most workers in the
field that FCPD is the logical end point of TCP and
enough evidence exists to suggest that TCP is the pre-dia-
betic stage of FCPD [3]. Thus, we also analyzed the associ-
ation of TCF7L2 variants in the entire cohort irrespective
of their diabetic status. In addition, clinical presentation is
known to be variable for FCPD [1,2]. Most of the patients
present with pain abdomen and evidence of pancreatitis
and subsequently develop diabetes at a later stage; a small
proportion present with diabetes and are detected to have
pancreatic stones and calcification on subsequent investi-
gations [1,2]. It may be surmised that additional diabetes
susceptibility gene may account for the earlier phenotype
of diabetes. Hence, an attempt was also made to dichot-
omize the cohort into TCP and FCPD to investigate
whether FCPD patients have an additional risk due to
TCF7L2  polymorphisms. We also investigated whether
co-inheritance of TCF7L2 variants with the SPINK1 and
CTSB  mutations predisposes these patients to develop
diabetes.
Table 2: Estimates of the genotype and allele relative risks for the TCF7L2 variants in the cases and controls based on ethnicity
SNP* Het OR (95% CI) P Hom OR (95% CI) P &OR (95% CI) P
All cases vs all controls rs7903146 0.90 (0.70–1.15) 0.40 1.02 (0.67–1.55) 0.92 0.96 (0.80–1.16) 0.70
rs12255372 1.03 (0.80–1.34) 0.80 0.88 (0.52–1.49) 0.62 0.98 (0.80–1.21) 0.88
DR cases vs DR controls rs7903146 0.90 (0.64–1.27) 0.55 0.95 (0.54–1.68) 0.86 0.94 (0.73–1.21) 0.65
rs12255372 0.92 (0.63–1.36) 0.69 1.41 (0.60–3.30) 0.42 1.04 (0.76–1.41) 0.81
IE cases vs IE controls rs7903146 0.86 (0.57–1.30) 0.48 1.06 (0.54–2.08) 0.86 0.96 (0.71–1.29) 0.79
rs12255372 0.99 (0.65–1.48) 0.95 0.96 (0.42–2.23) 0.93 0.98 (0.71–1.36) 0.92
SNP, single nucleotide polymorphism; *baseline genotype at rs7903146-CC, rs12255372-GG; Het OR & Hom OR, genotype relative risk (GRR) for 
heterozygotes and homozygotes respectively (GRR was calculated by comparing with the baseline genotype); &, allelic OR; P, P value; DR, 
Dravidians; IE, Indo-European
Table 1: Allelic and genotypic frequencies for the TCF7L2 variants in TCP patients and controls of different ethnic groups
SNP 
(NCBI 36.2&)
Allele Dravidian Indo-Europeans Total Genotype Dravidian@ Indo-Europeans@ Total@
Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls
n = 333 n = 259 n = 145 n = 402 n = 478 n = 661 n = 333 n = 259 n = 145 n = 402 n = 478 n = 661
rs7903146 
(114748339)
C 0.71 0.70 0.72 0.71 0.73 0.71 CC 175 (52.6) 130 (50.2) 78 (53.8) 207 (51.5) 253 (53.0) 337 (51.0)
CT 126 (37.8) 104 (40.2) 53 (36.6) 160 (39.8) 179 (37.3) 264 (39.9)
T 0.29 0.30 0.28 0.29 0.27 0.29 TT 32 (9.6) 25 (9.7) 14 (9.7) 35 (8.7) 46 (9.6) 60 (9.1)
n = 332 n = 180 n = 144 n = 402 n = 476 n = 582 n = 332 n = 180 n = 144 n = 402 n = 476 n = 582
rs12255372 
(114798892)
G 0.77 0.78 0.78 0.78 0.77 0.78 GG 201 (60.5) 108 (60.0) 88 (61.1) 244 (60.7) 289 (60.7) 352 (60.5)
GT 110 (33.1) 64 (35.6) 48 (33.3) 135 (33.6) 158 (33.2) 199 (34.2)
T 0.23 0.22 0.22 0.22 0.23 0.22 TT 21 (6.3) 8 (4.4) 8 (5.6) 23 (5.7) 29 (6.1) 31 (5.3)
SNP, single nucleotide polymorphism; n, number of individuals; &, Chromosome position according to National Centre for Biotechnology Information (NCBI), Build 36.2, contig 
accession number NT 030059.12; @, values in the parentheses indicate percentage genotype frequencyBMC Medical Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2350/9/80
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Both the polymorphisms followed Hardy-Weinberg equi-
librium (p > 0.05) and on comparing the allele frequen-
cies within the ethnic groups, Dravidian patients vs
Dravidian controls and Indo-European patients vs Indo-
European controls, no significant differences were seen
(table 1), neither did the genotype relative risk differ sig-
nificantly between patients and controls (table 2). A meta-
analysis of all cases and control subjects from both ethnic-
ities, showed similar results for both SNPs in TCF7L2 gene
[(95%CI, 0.95–1.16; P = 0.63, Cochran's Q = 0.0092, P =
0.92 for rs7903146) and (95%CI, 1.01–1.29; P = 0.92,
Cochran's Q = 0.0482, P = 0.83 for rs12255372)] (fig 1).
In order to explore the possibility of association of
TCF7L2 variants with FCPD, the analysis was carried out
in TCP patients with diabetes (FCPD) and those without
diabetes separately. Allele and genotypic frequencies did
not differ significantly, between TCP patients and con-
trols, FCPD patients and controls and between TCP and
FCPD patients, suggesting lack of statistically significant
association of TCF7L2 polymorphisms with FCPD (table
3).
Association analysis of the total cohort after dichotomiza-
tion based on N34S SPINK1 and L26V CTSB mutation sta-
tus showed comparable allele and genotype frequencies
for rs7903146 in both groups, indicating that co-existence
Meta-analysis for association of TCF7L2 variants with TCP Figure 1
Meta-analysis for association of TCF7L2 variants with TCP. Forest plot showing results of meta analysis. Odds ratio 
for each study is represented by a block bounded by its confidence interval; Combined effect for the two studies has been cal-
culated using fixed effect model; A, rs7903146; B, rs12255372.
Odds  Lower  Upper  
ratio    limit   limit  P-value Z-value
Dravidian  0.94      0.73    1.21   0.65    -0.45
Indo-European  0.97      0.72    1.30   0.83    -0.22
Combined Effect  0.95     0.79    1.16   0.63     -0.49
Dravidian  1.04      0.76    1.41    0.81    0.24
Indo-European  0.98      0.71    1.36    0.92   -0.10
Combined Effect  1.01      0.81    1.26    0.91    0.11
Study name  Statistics for each study  Odds ratio and 95% CI
A
B
Table 3: Estimates of the genotype and allele relative risks for the TCF7L2 variants in the cases and controls based on clinical diagnosis
SNP* Het OR (95% CI) P Hom OR (95% CI) P &OR (95% CI) P
TCP (n = 286) vs Controls rs7903146 0.95 (0.71–1.28) 0.74 0.98 (0.59–1.61) 0.94 0.97 (0.78–1.21) 0.81
rs12255372 0.92 (0.68–1.26) 0.62 1.31 (0.72–2.36) 0.38 1.03 (0.81–1.31) 0.79
FCPD (n = 192) vs Controls rs7903146 0.82 (0.58–1.16) 0.27 1.08 (0.62–1.87) 0.78 0.95 (0.74–1.22) 0.69
rs12255372 1.03 (0.73–1.46) 0.86 0.89 (0.41–1.92) 0.76 0.99 (0.75–1.31) 0.94
TCP vs FCPD rs7903146 0.86 (0.58–1.28) 0.47 1.10 (0.58–2.08) 0.76 0.98 (0.73–1.30) 0.87
rs12255372 1.11 (0.75–1.65) 0.59 0.68 (0.30–1.55) 0.36 0.96 (0.70–1.31) 0.79
SNP, single nucleotide polymorphism; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; *baseline genotype at 
rs7903146-CC, rs12255372-GG; Het OR & Hom OR, genotype relative risk (GRR) for heterozygotes and homozygotes respectively (GRR was 
calculated by comparing with the baseline genotype); &, allelic OR; P, P valueBMC Medical Genetics 2008, 9:80 http://www.biomedcentral.com/1471-2350/9/80
Page 5 of 6
(page number not for citation purposes)
of these variants does not increase the risk of developing
diabetes in these patients (table 4). However, the minor
allele frequency for rs7903146 was different between TCP
and FCPD patients carrying the N34S SPINK1 variant but
did not reach statistical significance (OR = 1.59, 95% CI =
0.93–2.70, P = 0.09). Interestingly, similar analysis using
L26V CTSB variant showed a statistically significant asso-
ciation between TCP and FCPD patients carrying the
mutant allele compared to those without the variant (OR
= 1.69, 95% CI = 1.11–2.56, P = 0.013) (table 4). Similar
results were obtained on analysis of the rs12255372 vari-
ant in TCF7L2 gene (data not presented). This suggests
that co-existence of TCF7L2 variants and the variants pre-
dicting susceptibility to exocrine damage may interact to
determine the onset of diabetes in TCP patients. However,
this may need to be replicated in larger sample size since
there is a possibility of a chance association due to small
sample size.
We and others have earlier replicated the strong associa-
tion of TCF7L2 variants with T2D in Indian population
and provided evidence of its likely role in the pathogene-
sis of T2D by influencing both insulin secretion and insu-
lin resistance [20]. According to accelerator hypothesis,
T1D and T2D may share a common etiology of hypergly-
cemia-induced beta cell damage but T1D may have the
added effects of autoimmunity [31]. However, the lack of
association of TCF7L2 with T1D, as shown by Field et al.,
does not support the model of a shared major causal path-
way in T2D and T1D [32]. Hence the genes that determine
susceptibility to T1D must be different from the suscepti-
bility genes of T2D. This has important implications for
diabetes in TCP since overlapping features of T1D and
T2D are observed in FCPD. As the overall evidence for
association of TCF7L2 gene variants exceeds genome-wide
significance criteria (10-5) and clearly establishes TCF7L2
as a T2D susceptibility gene of substantial importance in
majority of populations world-wide [33] including Indian
population [20], it is less likely that T2D may have a sus-
ceptibility factor stronger than TCF7L2. A lack of associa-
tion of TCF7L2 with TCP or FCPD observed in our study,
may suggest a role for genes other than TCF7L2 to be pre-
dictive of susceptibility to T2D. Since there is debate about
the type of diabetes in TCP and FCPD, the lack of associa-
tion with TCF7L2, the gene most strongly associated with
T2D may suggest that the diabetes in TCP patients does
not have similar features as T2D.
Conclusion
As TCF7L2 is a major susceptibility gene for T2D, a lack of
association of TCF7L2  variants with TCP or FCPD
observed in our study suggests that T2D associated
TCF7L2 variants are not associated with diabetes in TCP
or the diabetes in TCP patients may not be similar to T2D.
Thus, although the variations in TCF7L2 increase the risk
for T2D and may affect insulin secretion, they do not alter
susceptibility to FCPD, the diabetes in TCP patients. How-
ever, co-inheritance of the TCF7L2 variants with the pan-
creatitis associated susceptibility variants in SPINK1 and
CTSB genes may predict the development of diabetes in
these patients, but these observations need to be con-
firmed independently.
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